Covivio SA (COV)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 43.82 |
|---|---|
| 52-week range | 42.36 – 62.80 |
| Return, 1 month / 3 months | −5.4% / −17.2% |
| Return, 1 year / 3 years | −21.9% / +33.6% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 22.2% |
| Worst drawdown (1 year) | -29.5% |
| Average daily value traded | 7.12M EUR |
| Dividend yield | 3.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Covivio is a French real estate company that owns and manages property across Europe, with a focus on offices, residential buildings and hotels. Its office and residential portfolios are concentrated in cities in France, Germany and Italy, while its hotel properties are operated by partner hotel groups under their own brands. The company works with corporate tenants, institutional investors and hospitality operators, and it is based in France.
On this site Covivio SA appears as a stock on the Euronext Paris (France), code COV, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Covivio SA (COV) trades on the Euronext Paris in France. It last closed at EUR 43.82 on 23 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 290 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.9% and over the last three months it fell 17.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -16.4% | ||
| From 52-week high | -29.5% | ||
| Momentum | 31 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.2% | ||
| 6-month return | -23.0% | ||
| 12-month return, skipping the last month | -17.4% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.5% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 7.12M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.5% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −1.1% |
|---|---|
| 1 month | −5.4% |
| 3 months | −17.2% |
| 6 months | −23.0% |
| 1 year | −21.9% |
| 3 years | +33.6% |
| 5 years | −26.3% |
Signals
| 50-day / 200-day average | 46.94 / 52.41 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.86 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Jul 2026 | EUR 0.0486 |
| 17 Mar 2026 | EUR 1.5000 |
| 30 Apr 2025 | EUR 1.0138 |
| 19 Apr 2024 | EUR 3.3000 |
| 24 Apr 2023 | EUR 2.4561 |
| 25 Apr 2022 | EUR 3.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.